Clot Busting Drugs Market is expected to reach USD 58.4 Billion by 2032 growing at a CAGR of 7.3% | Future Market Insights

As per Future Market Insights’ latest industry analysis, the valuation for the global clot busting drugs market is estimated to be around USD 28.8 Billion in 2022 and is projected to exhibit a CAGR growth of close to 7.3% over the forecast period, with an estimated valuation of USD 58.4 Billion in 2032.

The global market for clot busting drugs is expanding rapidly as a result of rapid molecular and biological customization in the clot-busting drugs and the increasing prevalence of cardiovascular diseases worldwide coupled with an increasing elderly population. In the forecast years, the clot busting drugs market is expected to increase at a significant rate due to the growing need for clot busting drugs in the prevention of heart attacks and strokes.

Explore Market Dynamics: Request Your Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3135363839

As clot busting drugs are not reaching the consumers as per the asked demand due to lack of awareness and the side effects of the drugs, thus companies are introducing novel clot busting drugs with minimal side effects at reasonable costs. This is expected to significantly improve the adoption and consumption of clot-busting drugs. The rising product launches and approvals are expected to further contribute to the market growth over the forecast period.

Key Takeaways: Clot Busting Drugs Market Trends and Regional Leaders

• USA Leads North America:

The United States commanded the North American clot busting drugs market with a valuation of USD 8.4 Billion in 2021, capturing 31.1% of the global market share. With over 800,000 strokes annually, of which 85% are ischemic, demand for clot busting drugs remains high and is expected to drive future growth.

• Germany Tops Europe:

Germany emerged as the front-runner in the European market, holding 7.6% of the global market share in 2021. The country’s high prevalence of hypertension—impacting nearly 50% of individuals over 60—is a key factor increasing the risk of stroke and, in turn, boosting demand for clot busting drugs.

• China Dominates East Asia:

China held the lion’s share of the East Asian market with USD 1.6 Billion in revenue as of 2021. Reforms in healthcare access, universal insurance, and the planned price reduction for over 400 drugs are projected to further accelerate the country’s market expansion.

• Top Product Segment – Anticoagulants:

Anticoagulants led globally with USD 9.9 Billion in 2021, accounting for 36.7% of the global share. Advancements in NOACs and increased adoption in emerging markets are expected to sustain this growth. Notably, Natco Pharma’s RPIGAT (rivaroxaban) exemplifies recent innovation in this space.

• Leading Indication – Pulmonary Embolism:

Pulmonary embolism topped the global market by indication, reaching USD 8.4 Billion in 2021. Rising cancer prevalence, with 10 million deaths in 2020 (WHO), and chemotherapy-associated risks are key drivers for this segment.

• Injectable Route Dominates Administration:

Injectables maintained dominance, accounting for over half of the global market share. Their continued growth is supported by rising chronic illnesses, the popularity of biologics, and the adoption of safety syringes and auto-injectors.

• Hospital Pharmacies as Leading Distribution Channel:

Hospital pharmacies generated nearly one-third of global revenue in 2021. Factors such as ease of access, comprehensive product availability, and strong patient compliance contribute to this segment’s market leadership.

“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report! https://www.futuremarketinsights.com/reports/clot-busting-drugs-market

Market Competition

The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:

• In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.

• AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).

Key Companies Profiled

Sanofi; Dr. Reddy’s Laboratories; Bayer AG; Boehringer Ingelheim Gmbh.; Genentech Inc.; Eli Lilly and Company; Johnson & Johnson Services Inc.; The Medicines Company; Pfizer Inc.

Key Segments Covered in Clot Busting Drugs Industry Research

By Product:

• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

By Indication:

• Pulmonary Embolism
• Deep Vein Thrombosis
• Atrial Fibrillation
• Others

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacy
• Drug Store
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Drive Your Business Forward with Healthcare Insights! https://www.futuremarketinsights.com/industry-analysis/therapy-area

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube